The Department of Clinical Science is going to use the new strategic plan actively as emphasized in the editorial of Per last week. In one of the paragraphs on Recruitment Strategy (RIK1-T2), we wrote that:
Department of Clinical Science will stimulate group leaders to identify outstanding internal and external (foreign) candidates and submit names of potential candidates to the Department which will follow up these candidates with career counseling by the research advisor.
Aftergrowth is important for the Department. I encourage you all to let us know the names that may be relevant when the Department will plan future permanent academic positions. We wish to recruit outstanding candidates, whether they are located in Bergen or abroad. We have written merit-based criteria in addition to need-based criteria in the strategic plan. As merits we have emphasized high impact publications with high citation levels and key author roles, increasing trend in the publication quality and quantity, early achievement of a high h-index and demonstrated independence and ability to obtain external funding and teaching merits.
Below the title of the two speeches as Professor Bass Hassan – a leading oncologist and researcher at Lincoln College and Sir William Dunn School of Pathology, University of Oxford. Place: Stort Auditorium, Sentralblokken, HUS June 1st 11.30 AM (1) and 1:00 PM (2).
The first lecture is particularly interesting for biologists and basic researchers and clinicians interested in translational cancer Research.
The second lecture is more geared toward physicians / clinicians and discusses the role that genomics can play in oncology subject.
The lectures are planned directly transferred to the Norwegian Radium Hospital and Stavanger University Hospital.
- Kl. 11.45 AM “Evolution and translation of the IGF2:IGF2R interaction”
Focused on Bass Hassan’s main laboratory work: the evolution of the protein interaction between the products of two imprinted genes, genes that are also deregulated in cancer.
- Kl. 1:00 PM “Oncology in rare cancers, what we do and don’t know”
A general update on oncology in rare cancers such as sarcoma which will include where genomics might and might not have impact. Aspects of GIST as well as bone and soft tissue oncology will be presented, and discussion encouraged.
We wish to invite you all to the next K1/K2 Seminar in 2016. Wednesday June 1!
Arnt-Ove Hovden, PhD, MSc, Medical Manager Respiratory, Boehringer Ingelheim Norway KS
A PhD completed –so what now? As an alumni of Gades institute (now a part of K2), I will talk about what to expect after graduating and for many -leaving the safe haven of academia. I will focus on the experiences that I have had after changing career path, first into the biotech sector and later into the pharmaceutical industry at Boehringer Ingelheim. As my current role is Medical Manager for a lung disease (Idiopathic lung fibrosis), I will also discuss that as to how a background from for instance the K2 institute, might be very valuable for the industry and how that has enabled me to work with a novel drug targeting FGFR, PDGF and VEGF. The main focus of my talk will, however, be the transferable skills that you develop during your studies and how that will serve you well in the rest of your professional career. Questions are encouraged, with the aim of broaden your horizons and perhaps give rise to new ideas of how to plan for the time to come!
Time: Onsdag , 1 juni, 14.15-15.00
Place: Stort Auditorium, 3 etasje, Sentralblokken
Chair: Silke Appel
Pizza is served between 14:05-14.15.
Everyone is welcome.
See attachment for abstract.